Clinical trial
Study Evaluating MYO-029 in Adult Muscular Dystrophy
NCT00104078 · Wyeth is now a wholly owned subsidiary of Pfizer, Industry · Completed
Key facts
| NCT number | NCT00104078 |
|---|---|
| Title | Study Evaluating MYO-029 in Adult Muscular Dystrophy |
| Lead sponsor | Wyeth is now a wholly owned subsidiary of Pfizer, Industry |
| Status | Completed |
| Phase | Phase 1/Phase 2 |
| Study type | Interventional |
| Conditions | Becker Muscular Dystrophy, Facioscapulohumeral Muscular Dystrophy, Limb-Girdle Muscular Dystrophy |
| Intervention type | Drug |
| Interventions | MYO-029 |
| Enrollment | 108 |
| Start date | Feb 1, 2005 |
| Completion | Jan 1, 2007 |
| First posted | Feb 23, 2005 |
| Last update posted | Dec 28, 2007 |
| Countries | United States |
At a glance
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: